We are live on ! Find out more
ESLA icon

Estrella Immunopharma
ESLA

9 hedge funds and large institutions have $8.18M invested in Estrella Immunopharma in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

13% more funds holding

Funds holding: 8 → 9 (+1)

1% more capital invested

Capital invested by funds: $8.09M → $8.18M (+$94.4K)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.4% less ownership

Funds ownership: 32.8% → 32.4% (-0.4%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
9
Holders Change
+1
Holders Change %
+12.5%
% of All Funds
0.14%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CS
Clear Street
New York
+$321K
2
FIA
FNY Investment Advisers
New York
+$53.9K

Top Sellers

Rank Fund Capital Flow
1
CM
Crestline Management
Texas
-$233K
2
RCM
Robinson Capital Management
Michigan
-$119K
3
MC
Meteora Capital
Florida
-$119K
Name Holding Trade Value Shares
Change 		Change in
Stake
HHGC
1
Hunting Hill Global Capital
New York
$3.14M – – –
OCAM
2
Owl Creek Asset Management
New York
$2.76M – – –
SIA
3
SkyView Investment Advisors
New Jersey
$1.35M – – –
CS
4
Clear Street
New York
$322K +$321K +29,709 New
SOA
5
Sea Otter Advisors
Florida
$152K – – –
MC
6
Meteora Capital
Florida
$151K -$119K -10,987 -44%
RCM
7
Robinson Capital Management
Michigan
$137K -$119K -11,000 -47%
YCM
8
Yakira Capital Management
Connecticut
$110K – – –
FIA
9
FNY Investment Advisers
New York
$54K +$53.9K +5,000 New
CM
10
Crestline Management
Texas
– -$233K -21,990 Closed

ESLA Hedge Fund Activity: Q2 2023 in Review

9 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q2 2023, worth a combined $8.18M — up 1.2% from $8.09M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ESLA positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Clear Street, opening a new position worth an estimated $321K. The largest seller was Crestline Management, exiting entirely with an estimated $233K sold.

  • 9 institutional investors held Estrella Immunopharma (ESLA) as of Q2 2023, up from 8 in Q1 2023.
  • Funds reported $8.18M of Estrella Immunopharma stock for Q2 2023, up 1.2% quarter-over-quarter.
  • 2 funds opened new Estrella Immunopharma positions in Q2 2023 and 1 closed out, a net change of +1 holder.
  • The largest Estrella Immunopharma buyer in Q2 2023 was Clear Street, an estimated $321K added.
  • The largest Estrella Immunopharma seller in Q2 2023 was Crestline Management, an estimated $233K sold.

Based on aggregated 13F filings for Q2 2023.